The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion

What Was Tested

Researchers studied Glucagon and GIP (Gastric Inhibitory Polypeptide) in this randomized controlled trial publication.

Inhibition of dipeptidyl peptidase 4 by vildagliptin enhances the concentrations of the active form of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP).

The present study asked whether vildagliptin accentuates glibenclamide-induced hypoglycemia or affects endogenous secretion of GLP-1 and GIP after an oral glucose tolerance test.

Who Took Part

According to the abstract, 16 subjects were involved.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The subjects were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Neither the subjects nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

In the crossover set-up each of the subjects took both Glucagon and the comparison in turn, acting as their own control.

Blood was sampled to measure glucose, and total (sum of active and inactive) GLP-1 and GIP.

Statistical evaluation was done using repeated-measures ANOVA.

What Was Measured

Topics PubMed links to this paper include Adamantane, Algorithms, C-Peptide, Dipeptidyl-Peptidase IV Inhibitors, Drug Interactions, Enzyme-Linked Immunosorbent Assay and Gastric Emptying.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and GIP (Gastric Inhibitory Polypeptide) in 16 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Glucagon compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.